Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors

Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports

(2019) O. Lamy et al.   OSTEOPOROSIS INTERNATIONAL

Stopping Denosumab

(2019) Olivier Lamy et al.   Current Osteoporosis Reports

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline

(2019) Richard Eastell et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Spontaneous Vertebral Fractures in Males with Osteoporosis After Denosumab Discontinuation

(2019) Panagiotis Anagnostis et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women

(2019) A. Fassio et al.   BONE

Rebound vertebral fracture in the dental chair during a tooth extraction whilst on a treatment holiday from denosumab to avoid ONJ!

(2018) Alexandra Leaney et al.   BONE

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Certainties and Uncertainties About Denosumab Discontinuation

(2018) Elena Tsourdi et al.   CALCIFIED TISSUE INTERNATIONAL

Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates

(2018) Liana Tripto-Shkolnik et al.   CALCIFIED TISSUE INTERNATIONAL

Bone health during endocrine therapy for cancer

(2018) Tilman D Rachner et al.   Lancet Diabetes & Endocrinology

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis

(2017) R. Niimi et al.   OSTEOPOROSIS INTERNATIONAL

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

(2017) B. Uebelhart et al.   OSTEOPOROSIS INTERNATIONAL

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

(2017) T. Lehmann et al.   OSTEOPOROSIS INTERNATIONAL

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO

(2017)   SWISS MEDICAL WEEKLY

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report

(2016) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Michael Gnant et al.   LANCET

Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics

(2015) A. W. Popp et al.   OSTEOPOROSIS INTERNATIONAL

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE